Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) Products under Development by Stage of Development | 7 | 1 |
| Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) Products under Development by Therapy Area | 8 | 1 |
| Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) Products under Development by Indication | 9 | 1 |
| Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) Products under Development by Companies | 12 | 2 |
| Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) Therapeutics Assessment | 14 | 6 |
| Assessment by Monotherapy/Combination Products | 14 | 1 |
| Assessment by Mechanism of Action | 15 | 2 |
| Assessment by Route of Administration | 17 | 1 |
| Assessment by Molecule Type | 18 | 2 |
| Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) Companies Involved in Therapeutics Development | 20 | 2 |
| Hadasit Medical Research Services &Development Ltd | 20 | 1 |
| VM Discovery, Inc. | 21 | 1 |
| Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) Drug Profiles | 22 | 12 |
| Bryostatin-1 Drug Profile | 22 | 5 |
| DHACP-6 Drug Profile | 27 | 1 |
| Small Molecule to Activate Epsilon PKC for Ischemic Stroke Drug Profile | 28 | 1 |
| Small Molecule to Activate Epsilon PKC for Traumatic Brain Injury Drug Profile | 29 | 1 |
| Small Molecule to Activate PKC Epsilon for Neurology Drug Profile | 30 | 1 |
| Synthetic Peptide to Inhibit Protein Kinase C for Type 2 Diabetes and Insulin Resistance Drug Profile | 31 | 1 |
| VMD-1201 Drug Profile | 32 | 1 |
| VMD-2202 Drug Profile | 33 | 1 |
| Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) Dormant Projects | 34 | 1 |
| Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) Discontinued Products | 35 | 1 |
| Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) Featured News &Press Releases | 36 | 10 |
| Aug 15, 2016: Neurotrope Submits an Amended Protocol to the U.S. Food and Drug Administration for its Phase 2b Clinical Trial of its Lead | 36 | 1 |
| Jun 21, 2016: Bryostatin, a PKC epsilon Activator, Generates New Synapses Through Accumulation of the Synaptic Anchoring Protein PSD-95 at Neuronal Membranes | 36 | 1 |
| Jun 13, 2016: Neurotrope's Chief Scientific Officer Dr. Daniel Alkon Presents at the Gordon Conference: Drugs That Target Common Mechanisms for Synaptic Restoration in Mental Retardation and Alzheimer's Disease | 37 | 1 |
| Mar 08, 2016: Neurotrope Announces Publication Demonstrating Synaptic Regeneration with the PKC epsilon Activator Bryostatin, in a Fragile X Disease Late Brain Development Model | 38 | 1 |
| Feb 11, 2016: Neurotrope Doses First Patients in Phase 2b Study of Bryostatin for Treatment of Severe Alzheimer s Disease | 38 | 1 |
| Feb 03, 2016: Neurotrope Holds Investigators Meeting for U.S. Phase 2b Trial of Bryostatin-1 for Treatment of Alzheimer s Disease | 39 | 1 |
| Jan 07, 2016: Neurotrope Initiates Phase 2b Study of Bryostatin for Treatment of Alzheimer s Disease | 39 | 1 |
| Jul 20, 2015: Neurotrope to Showcase Bryostatin as a Potential Treatment for Alzheimer's Disease at the 2015 Alzheimer's Association International Conference | 40 | 1 |
| Jun 24, 2015: Neurotrope to Conduct Study on Niemann-Pick Type C, a Devastating Rare Pediatric Disease | 40 | 1 |
| Jun 12, 2015: Neurotrope to Present Findings of In-vitro Studies of Bryostatin's Effects on Niemann Pick Type C1 Cells at the Annual "Michael, Marcia &Christa Parseghian Scientific Conference" for Niemann-Pick Type C | 41 | 1 |
| Apr 16, 2015: Neurotrope Receives Research Grant From the FRAXA Research Foundation to Fund Pre-Clinical Fragile X Syndrome Behavioral Studies | 42 | 1 |
| Apr 09, 2015: Neurotrope Receives FDA Orphan Drug Designation for Bryostatin in the Treatment of Fragile X Syndrome | 42 | 1 |
| Apr 06, 2015: Neurotrope Selects Worldwide Clinical Trials to Commence Services for Phase 2B Trial of Bryostatin for the Treatment of Alzheimer's Disease | 43 | 1 |
| Mar 30, 2015: Severe Alzheimer's Patient Responds to Bryostatin Treatment | 44 | 1 |
| Mar 17, 2015: Neurotrope Announces Positive Final Results from Its Phase 2a Safety Study for the Treatment of Alzheimer s Disease | 45 | 1 |
| Appendix | 46 | 2 |
| Methodology | 46 | 1 |
| Coverage | 46 | 1 |
| Secondary Research | 46 | 1 |
| Primary Research | 46 | 1 |
| Expert Panel Validation | 46 | 1 |
| Contact Us | 46 | 1 |
| Disclaimer | 47 | 1 |
